A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53

A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53

Bibliographic Details
Main Authors:	Congcong Cao, Lin Yao, Aolin Li, Quan Zhang, Zhenan Zhang, Xiaofei Wang, Ying Gani, Yuchen Liu, Qian Zhang
Format:	Article
Language:	English
Published:	Wiley 2021-09-01
Series:	Clinical and Translational Medicine
Online Access:	https://doi.org/10.1002/ctm2.537

Similar Items

Evaluation of sgRNA target sites for CRISPR-mediated repression of TP53.
by: Ingrid E B Lawhorn, et al.
Published: (2014-01-01)

Therapeutic Editing of the <i>TP53</i> Gene: Is CRISPR/Cas9 an Option?
by: Regina Mirgayazova, et al.
Published: (2020-06-01)

<it>hTERT, MYC</it> and <it>TP53</it> deregulation in gastric preneoplastic lesions
by: Silva Tanielly Cristina, et al.
Published: (2012-07-01)

CRISPR screens are feasible in TP53 wild‐type cells
by: Kevin R Brown, et al.
Published: (2019-08-01)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
by: Emma Haapaniemi, et al.
Published: (2019-08-01)

TP53 and c-myc Co-alterations: A hallmark of oral cancer progression
by: Tanić Nasta, et al.
Published: (2013-01-01)

Synthetic Artificial Long Non-coding RNA Shows Higher Efficiency in Specific Malignant Phenotype Inhibition Compared to the CRISPR/Cas Systems
by: Lin Yao, et al.
Published: (2020-12-01)

TP53 and MDM2 alterations in human bladder cancer
by: Abdel-Fattah, Rana
Published: (1997)

Myc-induced liver tumors in transgenic zebrafish can regress in tp53 null mutation.
by: Lili Sun, et al.
Published: (2015-01-01)

Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9
by: Alex Olson, et al.
Published: (2020-10-01)

Tumor protein 53-induced nuclear protein 1 (TP53INP1) enhances p53 function and represses tumorigenesis
by: Jeyran eShahbazi, et al.
Published: (2013-05-01)

Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation.
by: Fuminori Tanihara, et al.
Published: (2018-01-01)

Mechanisms of transcriptional repression by the proto-oncogene c-Myc
by: Lapham, Abigail
Published: (2005)

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system
by: Zhang, Feng, et al.
Published: (2013)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
by: Guang Wu, et al.
Published: (2019-12-01)

TP53 Gene Polymorphism Modulates Bladder Cancer Incidence、Invasiveness and Prognosis
by: Hung-Yu Lin, et al.
Published: (2012)

Improving transgene expression and CRISPR‐Cas9 efficiency with molecular engineering‐based molecules
by: Hengji Zhan, et al.
Published: (2020-10-01)

Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis.
by: Silvia Pineda, et al.
Published: (2014-01-01)

The clinical significance and analysis of DNA microsatellites and TP53 associated changes in bladder cancer
by: Qureshi, Khaver Naseer
Published: (2002)

The TP53 fertility network
by: Diego d'Avila Paskulin, et al.
Published: (2012-01-01)

Progress of TP53 Family Gene TP73 and Tumorigenesis
by: XU Jie, et al.
Published: (2021-02-01)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
by: Dmitriy Sonkin
Published: (2015-10-01)

Evaluation of HER2, MDM2, MYC, MET and TP53 gene copy number alterations in gastric cancer patients
by: Fatemeh Nevisi, et al.
Published: (2020-01-01)

MYC, TP53, and Chromosome 17 Copy-Number Alterations in Multiple Gastric Cancer Cell Lines and in Their Parental Primary Tumors
by: Mariana Ferreira Leal, et al.
Published: (2011-01-01)

Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.
by: Elisabeth Silden, et al.
Published: (2013-01-01)

A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
by: Yann Neuzillet, et al.
Published: (2012-01-01)

The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis
by: Jiang, N., et al.
Published: (2021)

Unscheduled HDAC4 repressive activity in human fibroblasts triggers TP53‐dependent senescence and favors cell transformation
by: Harikrishnareddy Paluvai, et al.
Published: (2018-12-01)

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
by: Qiong Lyu MD, et al.
Published: (2020-12-01)

Transcriptional repression of GIF1 by the KIX-PPD-MYC repressor complex controls seed size in Arabidopsis
by: Zupei Liu, et al.
Published: (2020-04-01)

Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems
by: Fei Zhang, et al.
Published: (2019-06-01)

CRISPR transcriptional repression devices and layered circuits in mammalian cells
by: Kiani, Samira, et al.
Published: (2015)

Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
by: Dong, Y., et al.
Published: (2022)

TP53 in Biology and Treatment of Osteosarcoma
by: Kamil Jozef Synoradzki, et al.
Published: (2021-08-01)

The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers
by: Magali Olivier, et al.
Published: (2007-02-01)

Intronic <i>TP53</i> Polymorphisms Are Associated with Increased <i>Δ133TP53</i> Transcript, Immune Infiltration and Cancer Risk
by: Ramona A. Eiholzer, et al.
Published: (2020-09-01)

DOR/Tp53inp2 and Tp53inp1 constitute a metazoan gene family encoding dual regulators of autophagy and transcription.
by: Ana Sancho, et al.
Published: (2012-01-01)

CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites
by: Rajeswari Jayavaradhan, et al.
Published: (2019-06-01)

Drug Inducible CRISPR/Cas Systems
by: Jingfang Zhang, et al.
Published: (2019-01-01)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
by: Xuerui Li, et al.
Published: (2020-07-01)

Cannot write session to /tmp/vufind_sessions/sess_bj1sc4lbqabtovqus86rssml8k